US 12371506
Subcutaneous administration of anti-CD38 antibodies
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 12371506 (Subcutaneous administration of anti-CD38 antibodies) held by Takeda Pharmaceutical Company Limited expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61P